Efficacy and safety of canagliflozin in type 2 diabetes mellitus: Systematic review of randomized controlled trials

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 1, 2016, Pages 105-115

  Parveen, Rizwana ^a   Agarwal, Nidhi Bharal ^a   Kaushal, Neelam ^b   Mali, Ghanshyam ^b   Raisuddin, Sheikh ^a  

^a HAMDARD UNIVERSITY   (India)

^b Medical Affairs and Clinical Research   (India)

Author keywords

canagliflozin; oral hypoglycemics; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA; GLUCOSE BLOOD LEVEL;

ABDOMINAL PAIN; ALLERGIC REACTION; ARTHRALGIA; BACKACHE; BODY WEIGHT; BREAST CANCER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM METASTASIS; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FAINTNESS; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY CANCER; LUNG CANCER; MENINGIOMA; META ANALYSIS; MONOTHERAPY; MYCOSIS; NAUSEA; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHOTOTOXICITY; POLLAKISURIA; POLYURIA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THIRST; UPPER RESPIRATORY TRACT INFECTION; URINARY URGENCY; UTERINE CERVIX CANCER; UTERUS CANCER; XEROSTOMIA; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

BLOOD GLUCOSE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84955689826     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1109629     Document Type: Review

References (45)

1. Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract. 2013;67(12):1267-1282.
2. Nadeau DA. Physiologic and weightfocused treatment strategies for managing type 2 diabetes mellitus: The metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. Postgrad Med. 2013;125(3):112-126.
3. Zinman B. Initial combination therapy for type 2 diabetes mellitus: Is it ready for prime time? Am J Med. 2011;124(Suppl 1):S19-S34.
4. Hinnen D. The role of the kidney in hyperglycemia: A new therapeutic target in type 2 diabetes mellitus. J Cardiovasc Nurs. 2013;28(2):157-165.
5. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382 (9896):941-950.
6. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16 (5):467-477.
7. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232-1238.
8. Kaushal S, Singh H, Thangaraju P, et al. Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus. N Am J Med Sci. 2014;6(3):107-113.
9. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose cotransport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375-393.
10. Summary of product characteristics of INVOKANA. UK: Janssen-Cilag Ltd. [revised 2014 Nov 15; cited 2015 Jan 23]. Available from: Http://ec.europa.eu/health/documents/community-register/2013/20131115127004/anx-127004-en.pdf
11. Prescribing information of INVOKANA® . Silver Spring (MD): Janssen Pharmaceuticals Inc. [revised 2014 Feb 19; cited 2014 Mar 30]. Available from: Http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseac tion=Search.Label-ApprovalHistory#labelinfo.
12. Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud. 2011;8:348-354.
13. Kanwal A, Banerjee SK. SGLT inhibitors: A novel target for diabetes. Pharm Pat Anal. 2013;2(1):77-91.
14. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig. 2014;5 (3):265-275.
15. Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453-467.
16. Dietrich E, Powell J, Taylor JR. Canagliflozin: A novel treatment option for type 2 diabetes. Drug Des Devel Ther. 2013;7:1399-1408.
17. Colleen M, George LB. Blood pressure reduction: An added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38:429-430.
18. Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5):e001007.
19. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-382.
20. Panic N, Leoncini E, Belvis G, et al. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS ONE. 2013;8(12):e83138.
21. Berhan A, Barker A. Sodium glucose cotransport 2 inhibitors in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized double-blind controlled trials. Endocr Disord. 2013;13:58.
22. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia. 2013;56:2582-2592.
23. A randomized, double-blind, placebo-controlled, double-dummy, parallel group, multileft, dose-ranging study in subjects with type 2 diabetes mellitus to evaluate the efficacy, safety, and tolerability of orally administered SGLT2 inhibitor JNJ-28431754 with sitagliptin as a reference arm [cited 2014 Mar 15]. Available from: Https://www.clinicaltrials.gov/ct2/show/record/NCT00642278?term= NCT00642278&rank=1.
24. Schernthaner G, Jorge LG, Julio R, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care. 2013;36:2508-2515.
25. An efficacy, safety, and tolerability study of canagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin alone or in combination with a sulphonylurea [cited 2014 Mar 15]. Available from: Http://clinical trials.gov/ct2/show/NCT01381900?term= 01381900&rank=1.
26. Bode B, Stenlöf K, Sullivan D, et al. A safety and efficacy study of canagliflozin in older patients (55 to 80 years of age) with type 2 diabetes mellitus. Hosp Pract (1995). 2013;41(2):72-84.
27. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;5:463-473.
28. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14 (6):539-545.
29. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, doubleblind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136-1145.
30. An efficacy, safety, and tolerability study of canagliflozin in patients with type 2. Diabetes mellitus who have moderate renal impairment [cited 2014 Mar 15]. Available from: Http://clinicaltrials.gov/ct2/show/NCT01064414?term= nct01064414&rank=1.
31. Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163-175.
32. Nobuya I, Kazuoki K, Toru Y, et al. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study. J Diabetes Invest. 2015;6:210-218.
33. Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis. PLoS ONE. 2015;10(4):e0125879.
34. Mikhail N. Place of sodium-glucose cotransporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes. 2014;5(6):854-859.
35. Hao WL, Chin HT. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:6. Article ID 719578.
36. Mujahid AS, Parth N. Dapagliflozin for the treatment of type 2 diabetes: A review of the literature. Drug Des Devel Ther. 2014;8:2493-2505.
37. Sanjay K, Rakesh S, Yashdeep G. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab. 2015;19(4):524-528.
38. Juan FM, Lillian S, Emily E, et al. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes. A drug class overview. P T. 2015;40(7):451-462.
39. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38 (9):1687-1693.
40. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38 (9):1680-1686.
41. Summary of product characteristics of INVOKANA. UK: Janssen-Cilag Ltd. [revised 2015 Aug 20; cited 2015 Aug 30]. Available from: Https://www.medicines. org.uk/emc/medicine/28401.
42. Silvio E, Richard MB, John BB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-lefted approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.
43. Dennis JC, Terri LL, Danial EB. Formulary drug reviews: Dapagliflozin. Hosp Pharm. 2014;49(7):647-662.
44. Yehuda H, Zachary TB, George G, et al. American association of clinical endocrinologists and American College of Endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract. 2015;21(Suppl 1):1-87.
45. Nigro SC, Riche DM, Pheng M, et al. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother. 2013;47 (10):1301-1311.